These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32189156)

  • 1. Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
    Ando K; Emi Y; Miyanari N; Tsuji A; Sakai K; Sawai T; Imamura H; Mori S; Tokunaga S; Oki E; Saeki H; Kakeji Y; Akagi Y; Baba H; Maehara Y; Mori M;
    Int J Clin Oncol; 2020 Jun; 25(6):1115-1122. PubMed ID: 32189156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial.
    Sunami E; Kusumoto T; Ota M; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Okabe M; Tanaka C; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Takenaka N; Okude R; Sugihara K
    Clin Colorectal Cancer; 2020 Mar; 19(1):22-31.e6. PubMed ID: 31917122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
    Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
    Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
    Trials; 2013 Jan; 14():17. PubMed ID: 23320901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001).
    Ozawa M; Watanabe J; Ishibe A; Goto K; Fujii Y; Nakagawa K; Suwa Y; Suwa H; Masui H; Sugita M; Mochizuki Y; Yamagishi S; Hasegawa S; Homma Y; Momiyama M; Kumamoto T; Matsuyama R; Takeda K; Taguri M; Endo I
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):565-573. PubMed ID: 38374403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wei PL; Sung YC; Tang HC; Wang JY
    Trials; 2017 Apr; 18(1):191. PubMed ID: 28441966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer.
    Wang G; Zhao J; Song Y; Zhang W; Sun Y; Zhou A; Huang J; Du F; Yang L
    BMC Cancer; 2018 May; 18(1):547. PubMed ID: 29743043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
    Danno K; Hata T; Tamai K; Fujie Y; Ide Y; Kim HM; Ohnishi T; Morita S; Yoshioka S; Kudo T; Nishimura J; Matsuda C; Akamatsu H; Mizushima T; Nezu R; Doki Y; Mori M; ;
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):777-785. PubMed ID: 28825216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.
    Li N; Wu H; Xu X; Wei Q; Ding Y; Liu S; Wu J; Zheng Y; Xu N; Gao Y; Jiang H
    Sci Rep; 2024 Jul; 14(1):15150. PubMed ID: 38956232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.
    Watanabe J; Sasaki S; Kusumoto T; Sakamoto Y; Yoshida K; Tomita N; Maeda A; Teshima J; Yokota M; Tanaka C; Yamauchi J; Uetake H; Itabashi M; Takahashi K; Baba H; Kotake K; Boku N; Aiba K; Morita S; Takenaka N; Sugihara K
    ESMO Open; 2021 Apr; 6(2):100077. PubMed ID: 33714860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
    Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
    Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
    Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
    Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
    Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
    BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.